---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112054"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T08:54:50.617901+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics merges with Crescent in reverse acquisition; uproleselan trial fails

## Summary
- Crescent stockholders will own ~86.21% of combined company; GlycoMimetics stockholders ~13.79%.
- Concurrent $200M PIPE financing from institutional investors; closing conditioned on merger.
- NCI Phase 2/3 trial of uproleselan in AML failed to show statistically significant improvement in EFS or OS.
- Merger expected to close in Q2 2025; combined company to be led by Crescent's CEO and board.
- Support agreements cover ~98% of Crescent stock and ~9% of GlycoMimetics stock; 180-day lock-up.

## SEC filing metadata
- accession: 0001104659-24-112054
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000110465924112054/0001104659-24-112054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000110465924112054/tm2427013d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112054
- JSON: https://secwatch.observer/filing/0001104659-24-112054.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.